Core Viewpoint - The stock price of Juzi Biotechnology (02367) has experienced significant volatility in 2023, with a 31.65% drop in October and a cumulative decline of 55.18% since reaching a peak of 85.14 HKD on May 20. A potential turning point was observed on October 23 when the company received NMPA approval for its recombinant type I α1 collagen freeze-dried fiber, marking a significant milestone for the company [1][4][10]. Stock Performance - As of October 22, Juzi Biotechnology's stock price had fallen by 31.65% in October alone, and since its peak on May 20, the total decline reached 55.18% [1]. - On October 23, following the approval news, the stock surged to a high of 43.92 HKD, reflecting a 13.72% increase within the first half-hour of trading, although it ultimately closed up by 6.68% [4]. Market Dynamics - The stock saw a strong performance from early January to mid-May, with a peak increase of 70% and a market capitalization exceeding 90 billion HKD [5]. - The stock's price was closely aligned with the upper Bollinger Band for about two-thirds of the trading days from January to early May, indicating a strong upward trend [6]. - Following a downturn starting in late May, the average trading volume increased significantly, indicating heightened market activity and investor interest [7]. Management Actions - To bolster market confidence, the management of Juzi Biotechnology has been actively increasing their holdings. As of October 16, shareholders had purchased 391,660 shares, investing approximately 198 million HKD, achieving 99.2% of their planned buyback [8]. Industry Context - The approval of the recombinant collagen product is crucial for Juzi Biotechnology, especially in light of competition in the recombinant collagen market, which is projected to grow significantly [10][13]. - The Chinese recombinant collagen market is expected to exceed 193.7 billion RMB by 2027, with a compound annual growth rate of 35%, indicating a robust growth trajectory compared to traditional hyaluronic acid products [10]. - Juzi Biotechnology's unique position in the market, particularly with its proprietary technology for producing type III collagen, provides a competitive edge, although the recent approval of type I collagen is also a significant step forward for the company [13].

Core Viewpoint - The stock price of Juzi Bio (02367) has experienced significant volatility in 2023, with a 31.65% drop in October and a cumulative decline of 55.18% since reaching a peak of 85.14 HKD on May 20. The stock showed signs of stabilization on October 23 after receiving NMPA approval for its recombinant type I α1 collagen freeze-dried fiber, obtaining a Class III medical device registration certificate [1][4]. Group 1: Stock Performance - Juzi Bio's stock price surged by 13.72% to a high of 43.92 HKD shortly after the approval announcement on October 23, ending a streak of 14 consecutive days of decline [4]. - The stock had previously seen a strong performance from early January to mid-May, with a peak increase of 70% and a market capitalization exceeding 90 billion HKD [4][5]. - Following the peak, the stock began a downward trend, particularly after the "recombinant collagen not measurable" incident, leading to a cumulative drop of approximately 10% over three trading days from May 26 to 28 [7]. Group 2: Market Dynamics - The trading volume increased significantly after May, indicating a shift in market sentiment, with daily trading volumes exceeding 1 million shares from May 23 onward [7]. - The management of Juzi Bio has been actively buying back shares to boost market confidence, with a total of 391.66 million shares purchased for approximately 1.98 billion HKD, raising their holding to 54.56% [9]. - Despite the buyback efforts, the market response has shown diminishing returns, with minimal stock price increases following announcements of share purchases [9]. Group 3: Industry Context - The approval of the recombinant type I α1 collagen is crucial for Juzi Bio, as it allows the company to build a comprehensive product matrix from "cosmetic" to "medical" classifications [10][13]. - The Chinese recombinant collagen market is projected to exceed 193.7 billion HKD by 2027, with a compound annual growth rate of 35%, significantly outpacing traditional hyaluronic acid products [10]. - Juzi Bio's technology in producing recombinant collagen is currently leading the industry by 3-5 years, which is a key factor for capital premium [13].

Core Insights - On October 23, 2025, Alibaba-W (09988), Pop Mart (09992), and SMIC (00981) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 4.975 billion, 4.666 billion, and 3.522 billion respectively [1][2] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Pop Mart (09992) also ranked as the top three, with trading amounts of 3.277 billion, 2.585 billion, and 2.360 billion respectively [1][2] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Hong Kong Stock Connect)** - Alibaba-W (09988): 4.975 billion, net inflow of 268 million - Pop Mart (09992): 4.666 billion, net inflow of 538 million - SMIC (00981): 3.522 billion, net inflow of 463 million - Meituan-W (03690): 2.699 billion, net inflow of 37.728 million - Huahong Semiconductor (01347): 2.359 billion, net outflow of 356 million - CNOOC (00883): 1.987 billion, net inflow of 529 million - Tencent Holdings (00700): 1.804 billion, net inflow of 102 million - Genscript Biotech (02367): 1.429 billion, net inflow of 279 million - Shandong Hi-Speed (00412): 1.359 billion, net inflow of 67.296 million - Xiaomi Group-W (01810): 1.350 billion, net inflow of 183 million [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)** - Alibaba-W (09988): 3.277 billion, net outflow of 115 million - SMIC (00981): 2.585 billion, net outflow of 37.824 million - Pop Mart (09992): 2.360 billion, net inflow of 255 million - Huahong Semiconductor (01347): 1.624 billion, net outflow of 659 million - Meituan-W (03690): 1.534 billion, net inflow of 487 million - Tencent Holdings (00700): 1.217 billion, net inflow of 163 million - CNOOC (00883): 1.167 billion, net inflow of 451 million - Xiaomi Group-W (01810): 1.054 billion, net outflow of 240 million - Genscript Biotech (02367): 826 million, net inflow of 80.645 million - Innovent Biologics (01801): 797 million, net outflow of 14 million [2]

Group 1 - Southbound funds net bought Hong Kong stocks worth 5.345 billion HKD today [1] - The top net purchases included China National Offshore Oil Corporation (CNOOC) at 979 million HKD, Pop Mart at 793 million HKD, and Meituan-W at 524 million HKD [1] - Southbound funds have net bought Pop Mart for three consecutive days, totaling 2.15428 billion HKD, and have also net bought SMIC for three consecutive days, totaling 1.19602 billion HKD [1] Group 2 - Alibaba-W saw a net purchase of 268 million HKD despite a 1.7% decline [3] - CNOOC experienced a 2.2% increase with a net purchase of 529 million HKD [3] - Tencent Holdings had a net purchase of 163 million HKD with a 1.5% increase [3]

Core Insights - The Hong Kong stock market saw a net inflow of 53.45 billion HKD from Northbound trading on October 23, with the Shanghai Stock Connect contributing 47.7 billion HKD and the Shenzhen Stock Connect contributing 5.75 billion HKD [1] Group 1: Stock Performance - The most bought stocks included CNOOC (00883), Pop Mart (09992), and Meituan-W (03690) [1] - The most sold stocks included Hua Hong Semiconductor (01347), Innovent Biologics (01801), and Xiaomi Group-W (01810) [1] Group 2: Individual Stock Details - CNOOC (00883) received a net buy of 9.79 billion HKD, driven by rising international oil prices due to sanctions on Russian oil companies [5] - Pop Mart (09992) saw a net buy of 7.93 billion HKD, with a reported sales growth of 245% to 250% in Q3, significantly exceeding Morgan Stanley's forecast [5] - Meituan-W (03690) had a net buy of 5.24 billion HKD, with strategic leadership changes indicating a focus on international expansion [6] - Semiconductor stocks showed divergence, with SMIC (00981) receiving a net buy of 4.25 billion HKD, while Hua Hong Semiconductor (01347) faced a net sell of 10.14 billion HKD due to concerns over its business sustainability [6] - Zai Lab (02367) received a net buy of 3.59 billion HKD following the approval of a new medical device [7] - Tencent (00700) and Alibaba-W (09988) had net buys of 2.65 billion HKD and 1.53 billion HKD, respectively, while Innovent Biologics (01801) and Xiaomi Group-W (01810) faced net sells of 1.4 billion HKD and 573 million HKD [7]

Core Insights - The Hong Kong stock market saw a net inflow of 53.45 billion HKD from northbound trading on October 23, with the Shanghai-Hong Kong Stock Connect contributing 47.7 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing 5.75 billion HKD [1] Group 1: Stock Performance - The most bought stocks included CNOOC (00883), Pop Mart (09992), and Meituan-W (03690) [1] - The most sold stocks included Hua Hong Semiconductor (01347), Innovent Biologics (01801), and Xiaomi Group-W (01810) [1] - CNOOC received a net buy of 9.79 billion HKD, driven by rising international oil prices due to sanctions on Russian oil companies [4] - Pop Mart saw a net buy of 7.93 billion HKD, with a reported sales growth of 245% to 250% in Q3, significantly exceeding Morgan Stanley's forecast [5] - Meituan-W received a net buy of 5.24 billion HKD, with strategic leadership changes indicating a focus on international expansion [5] Group 2: Sector Insights - Semiconductor stocks showed divergence, with SMIC (00981) receiving a net buy of 4.25 billion HKD, while Hua Hong Semiconductor faced a net sell of 10.14 billion HKD [5][6] - The demand for domestic advanced wafer foundry services is expected to rise due to the growth of AI applications and supportive policies [6] - Giant Biologics (02367) received a net buy of 3.59 billion HKD following the approval of a new medical device by the National Medical Products Administration [6]

Core Viewpoint - The company, Giant Bio (2367.HK), experienced a significant intraday stock increase of 13.72%, reaching HKD 43.92, following the announcement of receiving a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen freeze-dried fiber product [1] Group 1: Product Approval - The company’s wholly-owned subsidiary, Shaanxi Giant Bio Technology Co., Ltd., received the medical device registration certificate for its recombinant collagen product [1] - This product is designed for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - It is noted as the first recombinant type I natural sequence collagen injectable product approved in China, showcasing the company's core competencies in technology research and development [1] Group 2: Market Opportunities - The approval of this product enriches the company's product portfolio and presents new opportunities for business development in the skin rejuvenation market [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product marks a significant milestone for the company, enhancing its competitive edge in the skin rejuvenation market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate from the National Medical Products Administration of China for the recombinant type I α1 collagen product [1] - This product is the first recombinant natural sequence collagen injectable approved in China, indicating a breakthrough in the company's product offerings [1] Group 2: Market Opportunities - The approval of this product will enrich the company's product categories and provide new opportunities for business development in the skin rejuvenation market [1] - The company plans to gradually launch and promote this product in accordance with its business strategy, leveraging existing products, brands, and channels to enhance consumer experience [1] Group 3: Competitive Position - The approval reflects the company's core competencies in technology research and development as well as industrialization [1] - The company aims to solidify its leading position in the health and beauty sector through this new product offering [1]

Core Viewpoint - The company has received a medical device registration certificate for its recombinant type I α1 collagen freeze-dried fiber product, marking a significant advancement in its product offerings and potential market opportunities in the skin rejuvenation sector [1] Group 1: Product Approval - The product is the first recombinant type I natural sequence collagen injectable approved in China, showcasing the company's technological research and development capabilities [1] - The approval was granted through a joint review of device and drug assessments, highlighting the regulatory efficiency [1] Group 2: Market Opportunities - The new product will enhance the company's product portfolio and provide new opportunities for business development in the skin rejuvenation market [1] - The company plans to gradually launch and promote the product in accordance with its business strategy, aiming to offer a diverse experience to consumers [1] Group 3: Competitive Position - The approval reinforces the company's leading position in the health and beauty sector, allowing it to strengthen its existing products, brands, and channels [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its competitive edge in the skin rejuvenation market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the recombinant type I α1 collagen freeze-dried fiber product [1] - This product is the first recombinant type I natural sequence collagen injectable product approved in China, indicating a breakthrough in the industry [1] Group 2: Market Opportunities - The approval reflects the company's core competencies in technology research and development, as well as industrialization [1] - The new product will diversify the company's product offerings and create new opportunities for business development in the skin rejuvenation market [1] Group 3: Future Plans - The company plans to gradually launch and promote the product according to its business strategy [1] - There will be a focus on collaboration with existing products, brands, and channels to provide consumers with a more diverse experience [1] - The company aims to strengthen its leading position in the health and beauty sector [1]